CSF3 and common wart: All 13 patients with warts received a full treatment course of G-CSF, whereas 10 patients with warts received a full treatment course of plerixafor (patients M07 and M09 received only 2 and 1 months of treatment, respectively, in the equilibration phase for plerixafor, and patient M17 dropped out at month 6 of the treatment phase for plerixafor; none of these patients experienced wart regression).